• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

利用质谱法定量翻译后修饰来破译抗癌疗法的效力。

Decrypting the potency of anti-cancer therapeutics by using mass spectrometry to quantify post-translational modifications.

机构信息

Department of Biological Engineering, Massachusetts Institute of Technology, Cambridge, MA 02139 USA.

Center for Precision Cancer Medicine, Koch Institute for Integrative Cancer Research, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.

出版信息

Cell Rep Methods. 2023 May 22;3(5):100483. doi: 10.1016/j.crmeth.2023.100483.

DOI:10.1016/j.crmeth.2023.100483
PMID:37323574
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10261922/
Abstract

In a recent issue of , Zecha et al. present decryptM, an approach aimed at defining the mechanisms of action of anti-cancer therapeutics through systems-level analysis of protein post-translational modifications (PTMs). By using a broad range of concentrations, decryptM generates drug response curves for each detected PTM, enabling identification of drug effects at different therapeutic doses.

摘要

在最近的一期《 》中,Zecha 等人提出了 decryptM 方法,该方法旨在通过对蛋白质翻译后修饰(PTMs)的系统水平分析来定义抗癌治疗药物的作用机制。通过使用广泛的浓度范围,decryptM 为每个检测到的 PTM 生成药物反应曲线,从而能够在不同的治疗剂量下识别药物的作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e677/10261922/d90423bdfaa3/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e677/10261922/d90423bdfaa3/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/e677/10261922/d90423bdfaa3/gr1.jpg

相似文献

1
Decrypting the potency of anti-cancer therapeutics by using mass spectrometry to quantify post-translational modifications.利用质谱法定量翻译后修饰来破译抗癌疗法的效力。
Cell Rep Methods. 2023 May 22;3(5):100483. doi: 10.1016/j.crmeth.2023.100483.
2
Decrypting drug actions and protein modifications by dose- and time-resolved proteomics.通过时分辨和剂量分辨蛋白质组学解析药物作用和蛋白质修饰。
Science. 2023 Apr 7;380(6640):93-101. doi: 10.1126/science.ade3925. Epub 2023 Mar 16.
3
MSModDetector: a tool for detecting mass shifts and post-translational modifications in individual ion mass spectrometry data.MSModDetector:一种用于检测单离子质谱数据中质量位移和翻译后修饰的工具。
Bioinformatics. 2024 Jun 3;40(6). doi: 10.1093/bioinformatics/btae335.
4
Mass spectrometric analysis of histone variants and post-translational modifications.组蛋白变体和翻译后修饰的质谱分析。
Front Biosci (Schol Ed). 2009 Jun 1;1(1):142-53. doi: 10.2741/S14.
5
Identification of post-translational modifications via blind search of mass-spectra.通过对质谱进行盲目搜索来鉴定翻译后修饰。
Proc IEEE Comput Syst Bioinform Conf. 2005:157-66. doi: 10.1109/csb.2005.34.
6
New Strategies for Probing the Biological Functions of Protein Post-translational Modifications in Mammalian Cells with Genetic Code Expansion.利用遗传密码扩展技术在哺乳动物细胞中探测蛋白质翻译后修饰的生物学功能的新策略。
Acc Chem Res. 2023 Oct 17;56(20):2827-2837. doi: 10.1021/acs.accounts.3c00460. Epub 2023 Oct 4.
7
Post-Translational Modifications (PTMs), Identified on Endogenous Huntingtin, Cluster within Proteolytic Domains between HEAT Repeats.翻译结果:内源性亨廷顿蛋白上鉴定的翻译后修饰(PTMs)簇集在热重复区之间的蛋白水解结构域内。
J Proteome Res. 2017 Aug 4;16(8):2692-2708. doi: 10.1021/acs.jproteome.6b00991. Epub 2017 Jul 3.
8
Characterization of charge variants, including post-translational modifications and proteoforms, of bispecific antigen-binding protein by cation-exchange chromatography coupled to native mass spectrometry.采用阳离子交换色谱法结合天然质谱法对双特异性抗原结合蛋白的电荷变异体(包括翻译后修饰和蛋白构象)进行表征。
Talanta. 2024 Jan 1;266(Pt 1):125062. doi: 10.1016/j.talanta.2023.125062. Epub 2023 Aug 8.
9
Characterization of histone post-translational modifications during virus infection using mass spectrometry-based proteomics.利用基于质谱的蛋白质组学对病毒感染期间组蛋白的翻译后修饰进行表征。
Methods. 2015 Nov 15;90:8-20. doi: 10.1016/j.ymeth.2015.06.008. Epub 2015 Jun 17.
10
Post-translational modifications and mass spectrometry detection.翻译后修饰和质谱检测。
Free Radic Biol Med. 2013 Dec;65:925-941. doi: 10.1016/j.freeradbiomed.2013.08.184. Epub 2013 Aug 31.

引用本文的文献

1
Spectrometry and Its Application for the Detection of RNA-Binding Proteins: Advancements, Techniques and Challenges.光谱分析及其在RNA结合蛋白检测中的应用:进展、技术与挑战
Anal Sci Adv. 2025 Aug 6;6(2):e70026. doi: 10.1002/ansa.70026. eCollection 2025 Dec.
2
Lessons learned from phase 3 trials of immunotherapy for glioblastoma: Time for longitudinal sampling?从胶质母细胞瘤免疫治疗的 3 期试验中吸取的教训:是否需要进行纵向采样?
Neuro Oncol. 2024 Feb 2;26(2):211-225. doi: 10.1093/neuonc/noad211.

本文引用的文献

1
Decrypting drug actions and protein modifications by dose- and time-resolved proteomics.通过时分辨和剂量分辨蛋白质组学解析药物作用和蛋白质修饰。
Science. 2023 Apr 7;380(6640):93-101. doi: 10.1126/science.ade3925. Epub 2023 Mar 16.
2
Identification of Src Family Kinases as Potential Therapeutic Targets for Chemotherapy-Resistant Triple Negative Breast Cancer.鉴定Src家族激酶作为化疗耐药三阴性乳腺癌的潜在治疗靶点
Cancers (Basel). 2022 Aug 30;14(17):4220. doi: 10.3390/cancers14174220.
3
Multimodal platform for assessing drug distribution and response in clinical trials.
用于评估临床试验中药物分布和反应的多模态平台。
Neuro Oncol. 2022 Jan 5;24(1):64-77. doi: 10.1093/neuonc/noab197.
4
In-depth proteomic analysis of proteasome inhibitors bortezomib, carfilzomib and MG132 reveals that mortality factor 4-like 1 (MORF4L1) protein ubiquitylation is negatively impacted.深入的蛋白质组学分析表明,蛋白酶体抑制剂硼替佐米、卡非佐米和 MG132 会导致死亡率因子 4 样 1(MORF4L1)蛋白的泛素化受到负面影响。
J Proteomics. 2021 Jun 15;241:104197. doi: 10.1016/j.jprot.2021.104197. Epub 2021 Apr 10.
5
Cell Type-specific Adaptive Signaling Responses to KRAS Inhibition.细胞类型特异性适应性信号对 KRAS 抑制的反应。
Clin Cancer Res. 2021 May 1;27(9):2533-2548. doi: 10.1158/1078-0432.CCR-20-3872. Epub 2021 Feb 22.
6
Rituximab and obinutuzumab differentially hijack the B cell receptor and NOTCH1 signaling pathways.利妥昔单抗和奥滨尤妥珠单抗对B细胞受体和NOTCH1信号通路的劫持作用存在差异。
iScience. 2021 Jan 22;24(2):102089. doi: 10.1016/j.isci.2021.102089. eCollection 2021 Feb 19.
7
Integrating Phenotypic Search and Phosphoproteomic Profiling of Active Kinases for Optimization of Drug Mixtures for RCC Treatment.整合活性激酶的表型搜索和磷酸化蛋白质组分析以优化用于肾细胞癌治疗的药物组合。
Cancers (Basel). 2020 Sep 21;12(9):2697. doi: 10.3390/cancers12092697.
8
Systemic analysis of tyrosine kinase signaling reveals a common adaptive response program in a HER2-positive breast cancer.系统分析酪氨酸激酶信号转导揭示了 HER2 阳性乳腺癌中的一种常见适应性反应程序。
Sci Signal. 2019 Jan 22;12(565):eaau2875. doi: 10.1126/scisignal.aau2875.
9
Tracking cancer drugs in living cells by thermal profiling of the proteome.通过蛋白质组的热分析来追踪活细胞中的癌症药物。
Science. 2014 Oct 3;346(6205):1255784. doi: 10.1126/science.1255784. Epub 2014 Oct 2.
10
Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors.定量化学蛋白质组学揭示临床ABL激酶抑制剂的作用机制。
Nat Biotechnol. 2007 Sep;25(9):1035-44. doi: 10.1038/nbt1328. Epub 2007 Aug 26.